Antiretroviral concentration, redox indexes and progression markers in HIV-infected patientâ??s blood samples follow-up during six month

Abstract

Rosario G. Hernandez, Ivon G. Blanco, Alicia T. Reyes, Daniel P. Correa,Dayme H. Requejo, Yusimit B. Alfonso, Lizette G. del Valle, Olga S. L.Fernandez

Objective: Human immunodeficiency virus (HIV) infection is accompanied by metabolic and immunological dysfunctions. Oxidative stress has been associated to HIV infection, and also its relation to highly active antiretroviral therapy (HAART) is suggested. This study assessed the effect of HAART combination (zidovudine/lamivudine/nevirapine) on redox indexes (RI) and progression markers of disease while monitoring also drugs concentration in blood. Methods: Eighty HIV subjects (40 taking HAART and 40 non-HAART) and 40 supposedly healthy voluntaries (SHV) were recruited. Blood antiretroviral drug concentrations were assessed by high performance liquid chromatography for each patient. Also peroxidation potential (PP), glutathione, malondialdehyde, hydroperoxides, superoxide dismutase (SOD), catalase (CAT), advanced oxidation protein products, viral load (VL) and CD4 T lymphocyte subsets were measured at baseline and at 6 months. Results: Drug concentration follow-up verified compliance of therapeutic range in 76% and 79% of patients studied at baseline and at 6 months without statistical difference. The comparison between SHV and HIV patients groups showed significant differences in almost all RI (except in SOD activity). Significantly modified values were found in almost all RI (except in CAT activity and PP) at 6 months compared to the baseline. Non-significant differences were found between HIV-infected patients with respect to CD4. 78% of patients receiving treatment showed a VL reduction. Conclusion: The confirmation of therapeutic range and its benefits in HIV-infected patients combined with additional oxidative stress impact promoted an integral view approach to followup the infection.